Compare Bank of New York Mellon Corp (BNY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Mesoblast Limited — how do they compare? Bank of New York Mellon Corp trades at $161.36 (market cap $108.78B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Bank of New York Mellon Corp is far larger — about 49.2× Mesoblast Limited's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BNY | MESO | |
|---|---|---|
Market Cap | $108.78B | $2.21B |
Sector | Financials | Technology |
52-Week High | $162.35 | $20.96 |
52-Week Low | $101.00 | $12.88 |
Dividend Yield | 1.38% | — |
Enterprise Value | — | $2.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
